Cantor Fitzgerald reissued their buy rating on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report report published on Sunday morning. Cantor Fitzgerald currently has a $28.00 target price on the stock.

Other equities analysts have also issued reports about the stock. Noble Financial reiterated a buy rating on shares of TherapeuticsMD in a report on Wednesday, December 20th. Oppenheimer set a $10.00 target price on shares of TherapeuticsMD and gave the company a buy rating in a report on Wednesday, December 20th. Deutsche Bank set a $9.00 target price on shares of TherapeuticsMD and gave the company a buy rating in a report on Wednesday, December 20th. Jefferies Group reiterated a buy rating and set a $15.00 target price on shares of TherapeuticsMD in a report on Tuesday, September 26th. Finally, BidaskClub lowered shares of TherapeuticsMD from a buy rating to a hold rating in a report on Friday, September 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. TherapeuticsMD currently has an average rating of Buy and an average price target of $14.50.

TherapeuticsMD (NASDAQ TXMD) opened at $6.33 on Friday. TherapeuticsMD has a 1-year low of $3.50 and a 1-year high of $8.30. The stock has a market cap of $1,370.00, a P/E ratio of -16.23 and a beta of 1.06.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The firm had revenue of $4.42 million during the quarter, compared to analyst estimates of $5.36 million. During the same period last year, the business earned ($0.13) earnings per share. The business’s revenue was down 19.7% on a year-over-year basis. analysts expect that TherapeuticsMD will post -0.37 EPS for the current fiscal year.

In other news, Director Tommy G. Thompson acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was bought at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the acquisition, the director now directly owns 3,555 shares in the company, valued at $22,076.55. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 23.92% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP purchased a new position in TherapeuticsMD in the 3rd quarter worth approximately $528,000. Bamco Inc. NY raised its holdings in TherapeuticsMD by 8.2% in the 3rd quarter. Bamco Inc. NY now owns 920,000 shares of the company’s stock worth $4,867,000 after acquiring an additional 70,000 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in TherapeuticsMD in the 3rd quarter worth approximately $2,812,000. Wells Fargo & Company MN raised its holdings in TherapeuticsMD by 13.6% in the 3rd quarter. Wells Fargo & Company MN now owns 217,820 shares of the company’s stock worth $1,153,000 after acquiring an additional 26,007 shares during the last quarter. Finally, 1492 Capital Management LLC raised its holdings in TherapeuticsMD by 86.4% in the 3rd quarter. 1492 Capital Management LLC now owns 390,702 shares of the company’s stock worth $2,067,000 after acquiring an additional 181,115 shares during the last quarter. Institutional investors own 73.69% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Cantor Fitzgerald Reiterates Buy Rating for TherapeuticsMD (TXMD)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/cantor-fitzgerald-reiterates-buy-rating-for-therapeuticsmd-txmd/1802069.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with Analyst Ratings Network's FREE daily email newsletter.